Trioplus Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Trioplus Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Trioplus Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Trioplus Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antifungals Specialist · $1.1M Total Trade · DGFT Verified

Trioplus Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 2 products in 2 therapeutic categories. Based on 32 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ketoconazole ($600.0K), Chlorpheniramine ($493.9K), .

Trioplus Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Trioplus Pharmaceuticals Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Trioplus Pharmaceuticals Private Limited? — Company Overview & Market Position

Trioplus Pharmaceuticals Private Limited is an Indian pharmaceutical exporter established on July 23, 2013, in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U74999MH2013PTC246040. It operates as a private limited company, classified as a non-government entity, and is unlisted on stock exchanges. The authorized and paid-up capital of the company is ₹100,000 each.

The registered office is located at Unit No.106, Samruddhi Commercial Complex, Chincholi Bunder Road, Mindspace, Malad (West), Mumbai, Maharashtra, 400064. The company is engaged in pharmaceutical retail and distribution activities within the professional, scientific, and technical sector.

As of the latest available data, Trioplus Pharmaceuticals has reported a significant decrease in revenue, with a 47.71% decline in the financial year ending March 31, 2023. Profitability also experienced a substantial fall, with a 103.98% decrease in profit during the same period. The company's net worth dipped by 1.09% in the same fiscal year.

What Does Trioplus Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ketoconazole$600.0K

Product Portfolio — Top 2 by Export Value

Trioplus Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ketoconazole	Antifungals	$600.0K	12	1.5%	8
2	Chlorpheniramine	Antihistamines & Allergy	$493.9K	20	1.1%	12

Trioplus Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.1M. The top category is Antifungals (54.8% of portfolio), followed by Antihistamines & Allergy (45.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Trioplus Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Trioplus Pharmaceuticals' manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's operations primarily focus on the export of finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This strategic focus suggests that the company may rely on third-party manufacturers or contract manufacturing organizations (CMOs) for production. However, without explicit information, the exact nature of their manufacturing arrangements remains speculative.

3Key Leadership

Trioplus Pharmaceuticals is led by two directors:

Kunal Surendra Mehra: Appointed on July 23, 2013, he serves as a director of the company.

Neelav Rajmohan Agarwal: Also appointed on July 23, 2013, he holds the position of director.

The company's financial statements for the fiscal year ending March 31, 2023, were filed on March 31, 2023, and the Annual General Meeting (AGM) was held on September 30, 2023.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Trioplus Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Trioplus Pharmaceuticals' export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's total export value is $1.1 million USD, with 32 shipments across two therapeutic categories: antifungals and antihistamines & allergy medications. The top five products exported are Ketoconazole ($600K, Rank #8, 1.5% market share) and Chlorpheniramine ($494K, Rank #12, 1.1% market share). The primary markets for these products are not specified in the available data.

2Emerging Markets

Trioplus Pharmaceuticals' export data does not specify its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's focus on finished pharmaceutical formulations suggests potential opportunities in these regions, especially if the products meet the World Health Organization's (WHO) prequalification standards. However, without explicit information, the extent of the company's penetration into these markets remains unclear.

3Geographic Strategy

The available data does not provide detailed insights into Trioplus Pharmaceuticals' geographic diversification or concentration risks. The company's export portfolio is concentrated entirely on its top five products, indicating a lack of diversification in its product offerings. This concentration could pose risks if market dynamics change or if there are regulatory challenges in the primary export markets. A more diversified product portfolio and geographic presence could mitigate such risks.

Trioplus Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Trioplus Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, is not publicly available. The company's export data does not specify its presence in the U.S. market, and without explicit information, the extent of its engagement with the FDA remains unclear.

2WHO & EU GMP

There is no publicly available information indicating that Trioplus Pharmaceuticals has obtained World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certifications. These certifications are crucial for accessing certain international markets, and the absence of such certifications may limit the company's ability to export to regions that require them.

3CDSCO & Indian Regulatory

Trioplus Pharmaceuticals is registered with the Central Drugs Standard Control Organisation (CDSCO) in India, as indicated by its Corporate Identification Number (CIN) U74999MH2013PTC246040. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. Without this information, it is challenging to assess the company's compliance with Indian regulatory requirements.

Trioplus Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Trioplus Pharmaceuticals operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. The company's top five products—Ketoconazole and Chlorpheniramine—are common in the antifungal and antihistamine categories, respectively. Major competitors in these categories include global pharmaceutical companies with established market presence and extensive product portfolios. Trioplus Pharmaceuticals' market share of 1.5% for Ketoconazole and 1.1% for Chlorpheniramine indicates a modest position in the market. The company's lack of diversification in both product offerings and geographic markets may limit its ability to compete effectively against larger, more diversified competitors.

2Key Differentiators

Trioplus Pharmaceuticals' focus on finished pharmaceutical formulations, particularly in the antifungal and antihistamine categories, allows it to cater to specific therapeutic needs. However, the company's product portfolio is highly concentrated, with the top five products accounting for 100% of its exports. This lack of diversification may limit its ability to adapt to changing market demands and could pose risks if there are shifts in therapeutic trends or regulatory environments.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Trioplus Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Specific information regarding Trioplus Pharmaceuticals' manufacturing facilities, including locations, capacities, and specializations, is not publicly disclosed. The company's reliance on third-party manufacturers or contract manufacturing organizations (CMOs) is inferred from its focus on finished pharmaceutical formulations. Without explicit information, it is challenging to assess the company's track record, export volume consistency, and reliability indicators.

2Certifications to Verify

Importers should verify the following certifications when considering Trioplus Pharmaceuticals as a supplier:

FDA Registration: To ensure compliance with U.S. regulations, importers should confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official database.

WHO-GMP Certification: To access markets requiring WHO prequalification, importers should verify that the company's manufacturing facilities hold WHO-Good Manufacturing Practice (GMP) certification. This can be confirmed through the WHO's official website.

Frequently Asked Questions — Trioplus Pharmaceuticals Private Limited

How many pharmaceutical products does Trioplus Pharmaceuticals Private Limited export from India?

Trioplus Pharmaceuticals Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ketoconazole ($600.0K), Chlorpheniramine ($493.9K). Total export value is $1.1M.

What is Trioplus Pharmaceuticals Private Limited's total pharmaceutical export value?

Trioplus Pharmaceuticals Private Limited's total pharmaceutical export value is $1.1M, based on 32 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Trioplus Pharmaceuticals Private Limited cover?

Trioplus Pharmaceuticals Private Limited exports across 2 therapeutic categories. The largest are Antifungals (54.8%, 1 products), Antihistamines & Allergy (45.2%, 1 products).

Get Full Trioplus Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.